2011
DOI: 10.1371/journal.pone.0028951
|View full text |Cite
|
Sign up to set email alerts
|

Autoantibody Signature Differentiates Wilms Tumor Patients from Neuroblastoma Patients

Abstract: Several studies report autoantibody signatures in cancer. The majority of these studies analyzed adult tumors and compared the seroreactivity pattern of tumor patients with the pattern in healthy controls. Here, we compared the autoimmune response in patients with neuroblastoma and patients with Wilms tumor representing two different childhood tumors. We were able to differentiate untreated neuroblastoma patients from untreated Wilms tumor patients with an accuracy of 86.8%, a sensitivity of 87.0% and a specif… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
7
0
1

Year Published

2013
2013
2022
2022

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 7 publications
(8 citation statements)
references
References 41 publications
0
7
0
1
Order By: Relevance
“…Tumor-associated autoantibodies can be used as diagnostic tools. Despite that nephroblastomas have a much lower expression of autoantibodies than neuroblastomas, 72 , 73 differential autoantibody signatures allowed separation between WT patients, neuroblastoma patients, and healthy controls with sensitivity and specificity of more than 86%. 72 In WT patients not subjected to neoadjuvant chemotherapy, the autoantibodies contributing the most to the identification of WT patients were directed to the proteins ZFP 346 and fascin.…”
Section: Neoantigen Productionmentioning
confidence: 99%
“…Tumor-associated autoantibodies can be used as diagnostic tools. Despite that nephroblastomas have a much lower expression of autoantibodies than neuroblastomas, 72 , 73 differential autoantibody signatures allowed separation between WT patients, neuroblastoma patients, and healthy controls with sensitivity and specificity of more than 86%. 72 In WT patients not subjected to neoadjuvant chemotherapy, the autoantibodies contributing the most to the identification of WT patients were directed to the proteins ZFP 346 and fascin.…”
Section: Neoantigen Productionmentioning
confidence: 99%
“…To determine the frequency with which particular peptide clones are recognized by antibodies present in sera from patients with MG vs. healthy controls we used an arbitrarily defined cut-off, considering intensity values of ≥50 as positive and <50 as negative [26], [28]. The frequency of positive sera for a given peptide clone in each group was then calculated according to the formula [(number of sera with intensity values ≥50/(number of sera with intensity values ≥50 + number of sera with intensity values <50)] ×100%.…”
Section: Resultsmentioning
confidence: 99%
“…Evaluation of autoantibody profiles from protein macroarrays is based on the assumption that analysis of patterns of multiple antibody reactivities might be more informative than analysis of single autoantibodies alone [20]. Indeed, previous work performed in patients with various cancers as well as autoimmune diseases suggests that autoantibody profiles may have the potential to serve as disease biomarkers and to provide clues for disease pathogenesis [20], [21], [22], [23], [24], [25], [26]. Accordingly, a customized protein macroarray comprising 1827 potential human autoantigens recently developed in our laboratory permitted to adequately discriminate sera of patients with different cancers from sera of healthy controls [27], [28], [29].…”
Section: Introductionmentioning
confidence: 99%
“…In the field of SRBCT and the overlap of nephroblastoma and neuroblastoma two recent reports propose immunohistochemical markers, cyclin D1 and PHOX2B, to be reliable for distinction of neuroblastoma from other malignancies [ 21 , 22 ]. Different autoantibody signatures obtained from peripheral blood were detected with high sensitivity and specificity in untreated nephroblastoma and neuroblastoma patients, making this approach particularly interesting in the absence of histological samples [ 23 ]. In the case described in this study previous establishment of diagnostic signatures to distinguish SRBCT by gene expression analysis and a multiplex RT-PCR assay, the latter being extended for Wilms’ specific genes, allowed analysis of the patients’ tumor [ 24 ].…”
Section: Discussionmentioning
confidence: 99%